CO2018004968A2 - 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) - Google Patents
2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)Info
- Publication number
- CO2018004968A2 CO2018004968A2 CONC2018/0004968A CO2018004968A CO2018004968A2 CO 2018004968 A2 CO2018004968 A2 CO 2018004968A2 CO 2018004968 A CO2018004968 A CO 2018004968A CO 2018004968 A2 CO2018004968 A2 CO 2018004968A2
- Authority
- CO
- Colombia
- Prior art keywords
- apj
- apeline
- nicotinamides
- dihydroxy
- receptor agonists
- Prior art date
Links
- XUGMSMOGPBQWJC-UHFFFAOYSA-N 4-hydroxy-2-oxo-1h-pyridine-3-carboxamide Chemical class NC(=O)C1=C(O)C=CNC1=O XUGMSMOGPBQWJC-UHFFFAOYSA-N 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241367P | 2015-10-14 | 2015-10-14 | |
| US201562270659P | 2015-12-22 | 2015-12-22 | |
| PCT/US2016/056769 WO2017066402A1 (en) | 2015-10-14 | 2016-10-13 | 2,4-dihydroxy-nicotinamides as apj agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018004968A2 true CO2018004968A2 (es) | 2018-10-10 |
Family
ID=57178558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0004968A CO2018004968A2 (es) | 2015-10-14 | 2018-05-10 | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10392347B2 (enExample) |
| EP (1) | EP3362442B1 (enExample) |
| JP (1) | JP6837482B2 (enExample) |
| KR (1) | KR102707502B1 (enExample) |
| CN (1) | CN108368087B (enExample) |
| AU (1) | AU2016340264B2 (enExample) |
| BR (1) | BR112018007395A2 (enExample) |
| CA (1) | CA3001974A1 (enExample) |
| CL (1) | CL2018000953A1 (enExample) |
| CO (1) | CO2018004968A2 (enExample) |
| EA (1) | EA034857B1 (enExample) |
| ES (1) | ES2774945T3 (enExample) |
| IL (1) | IL258577B (enExample) |
| MX (1) | MX376824B (enExample) |
| PE (1) | PE20181197A1 (enExample) |
| SG (1) | SG10201908839QA (enExample) |
| TW (1) | TW201720796A (enExample) |
| UY (1) | UY36949A (enExample) |
| WO (1) | WO2017066402A1 (enExample) |
| ZA (1) | ZA201802451B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050317T2 (hu) | 2015-05-20 | 2020-11-30 | Amgen Inc | APJ receptor triazol agonistái |
| LT3303330T (lt) | 2015-06-03 | 2019-08-12 | Bristol-Myers Squibb Company | 4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui |
| JP6817305B2 (ja) | 2015-12-04 | 2021-01-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アペリン受容体アゴニストおよびその使用方法 |
| EP3390400B1 (en) | 2015-12-16 | 2021-01-20 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
| EA037162B1 (ru) | 2016-03-24 | 2021-02-12 | Бристол-Маерс Сквибб Компани | 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| CN109311821B (zh) | 2016-06-14 | 2022-10-14 | 百时美施贵宝公司 | 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮 |
| ES2844184T3 (es) * | 2016-06-14 | 2021-07-21 | Bristol Myers Squibb Co | 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ |
| KR102521956B1 (ko) * | 2016-10-14 | 2023-04-14 | 브리스톨-마이어스 스큅 컴퍼니 | 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제 |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| EP3541802B1 (en) | 2016-11-16 | 2025-01-01 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| WO2025153720A1 (en) * | 2024-01-19 | 2025-07-24 | Scenic Biotech Bv | Pla2g15 inhibitors |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH602664A5 (en) | 1973-06-14 | 1978-07-31 | Sandoz Ag | 2-Tert. amino-alkylamino-pyrimidine derivs. |
| ZA835878B (en) * | 1982-08-23 | 1985-03-27 | Warner Lambert Co | Cardiotonic agents |
| GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| DE4425616A1 (de) * | 1994-07-20 | 1996-01-25 | Basf Ag | Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung |
| CA2258949C (en) | 1996-07-01 | 2008-05-06 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| AU2001280590A1 (en) | 2000-07-18 | 2002-01-30 | Neurogen Corporation | 5-substituted 2-aryl-4-pyrimidinones |
| TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
| CN100491358C (zh) | 2002-05-09 | 2009-05-27 | 赛特凯恩蒂克公司 | 嘧啶酮类化合物、组合物及方法 |
| CA2483627A1 (en) | 2002-05-23 | 2003-12-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP2004339159A (ja) | 2003-05-16 | 2004-12-02 | Sankyo Co Ltd | ４−オキソキノリン誘導体を含有する医薬組成物 |
| US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005041888A2 (en) | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
| EP1697331A4 (en) | 2003-12-19 | 2010-08-04 | Merck Sharp & Dohme | INHIBITORS OF MITOTIC KINESINE |
| WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007037543A1 (ja) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | ビアリールアミド誘導体 |
| NZ568666A (en) | 2005-11-30 | 2011-09-30 | Vertex Pharma | [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met |
| EP2016056A4 (en) | 2006-04-21 | 2010-11-10 | Univ Boston | IONIC VISCOELASTIC AND VISCOELASTIC SALTS |
| JP2007308441A (ja) * | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| EP2079707B1 (de) | 2006-10-10 | 2014-12-03 | proionic GmbH & Co KG | Verfahren zur umsetzung von 1,3-hetero-aromatischen 2-carboxylaten mit wasser |
| WO2008052861A2 (de) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| WO2009129120A2 (en) | 2008-04-15 | 2009-10-22 | Rfs Pharma, Llc | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| WO2010072696A2 (de) | 2008-12-22 | 2010-07-01 | Basf Se | Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern |
| TW201100411A (en) | 2009-05-21 | 2011-01-01 | Chlorion Pharma Inc | Pyrimidines as novel therapeutic agents |
| US9212130B2 (en) | 2010-08-10 | 2015-12-15 | Shionogi & Co., Ltd. | Heterocyclic derivative and pharmaceutical composition comprising the same |
| JP5990262B2 (ja) | 2011-05-31 | 2016-09-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ヒドリド−トリシアノ−ボラートアニオンを含む化合物 |
| AU2012265220A1 (en) | 2011-05-31 | 2014-01-16 | Merck Patent Gmbh | Electrolyte formulations |
| US20140005181A1 (en) * | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| WO2014004676A1 (en) | 2012-06-26 | 2014-01-03 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors as neuroprotective agents in the cns |
| WO2014044738A1 (en) * | 2012-09-21 | 2014-03-27 | Sanofi | Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators |
| DE102012021452A1 (de) | 2012-10-31 | 2014-04-30 | Merck Patent Gmbh | Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion |
| US9670162B2 (en) | 2013-03-14 | 2017-06-06 | The Board Of Trustees Of The Leland Stanford Junio | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof |
| TN2015000547A1 (fr) | 2013-06-27 | 2017-04-06 | Pfizer | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 |
| WO2014207100A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | A process for coating paper with cellulose using a solution containing cellulose |
| ES2906062T3 (es) | 2013-11-29 | 2022-04-13 | Proionic Gmbh | Procedimiento para la unión de un material termoplástico por medio de radiación de microondas |
| WO2015184011A2 (en) | 2014-05-28 | 2015-12-03 | Sanford-Burnham Medical Research Institute | Agonists of the apelin receptor and methods of use thereof |
| KR102509043B1 (ko) * | 2014-06-06 | 2023-03-09 | 리써치 트라이앵글 인스티튜트 | 아펠린 수용체(apj) 효능제 및 이의 용도 |
| WO2016074757A1 (de) | 2014-11-11 | 2016-05-19 | Merck Patent Gmbh | Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren |
| EP3287443B1 (en) | 2015-04-24 | 2021-10-27 | Shionogi & Co., Ltd | 6-membered heterocyclic derivative and pharmaceutical composition comprising same |
| HUE050317T2 (hu) | 2015-05-20 | 2020-11-30 | Amgen Inc | APJ receptor triazol agonistái |
| LT3303330T (lt) | 2015-06-03 | 2019-08-12 | Bristol-Myers Squibb Company | 4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui |
| KR101711744B1 (ko) | 2015-07-16 | 2017-03-02 | 경희대학교 산학협력단 | 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층 |
| WO2017091513A1 (en) | 2015-11-24 | 2017-06-01 | Daiichi Sankyo Company, Limited | Novel azole derivatives as apelin receptor agonist |
| JP6817305B2 (ja) | 2015-12-04 | 2021-01-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アペリン受容体アゴニストおよびその使用方法 |
| EP3390400B1 (en) | 2015-12-16 | 2021-01-20 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
| EA037162B1 (ru) | 2016-03-24 | 2021-02-12 | Бристол-Маерс Сквибб Компани | 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj |
| ES2844184T3 (es) | 2016-06-14 | 2021-07-21 | Bristol Myers Squibb Co | 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ |
| CN109311821B (zh) | 2016-06-14 | 2022-10-14 | 百时美施贵宝公司 | 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮 |
| KR102521956B1 (ko) | 2016-10-14 | 2023-04-14 | 브리스톨-마이어스 스큅 컴퍼니 | 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제 |
-
2016
- 2016-10-13 CA CA3001974A patent/CA3001974A1/en not_active Abandoned
- 2016-10-13 ES ES16784732T patent/ES2774945T3/es active Active
- 2016-10-13 UY UY0001036949A patent/UY36949A/es unknown
- 2016-10-13 KR KR1020187013119A patent/KR102707502B1/ko active Active
- 2016-10-13 EA EA201890858A patent/EA034857B1/ru not_active IP Right Cessation
- 2016-10-13 JP JP2018519425A patent/JP6837482B2/ja active Active
- 2016-10-13 BR BR112018007395A patent/BR112018007395A2/pt not_active IP Right Cessation
- 2016-10-13 EP EP16784732.6A patent/EP3362442B1/en active Active
- 2016-10-13 SG SG10201908839Q patent/SG10201908839QA/en unknown
- 2016-10-13 US US15/767,364 patent/US10392347B2/en active Active
- 2016-10-13 MX MX2018004344A patent/MX376824B/es active IP Right Grant
- 2016-10-13 CN CN201680072835.5A patent/CN108368087B/zh active Active
- 2016-10-13 AU AU2016340264A patent/AU2016340264B2/en not_active Ceased
- 2016-10-13 WO PCT/US2016/056769 patent/WO2017066402A1/en not_active Ceased
- 2016-10-13 PE PE2018000536A patent/PE20181197A1/es unknown
- 2016-10-13 TW TW105133123A patent/TW201720796A/zh unknown
-
2018
- 2018-04-09 IL IL258577A patent/IL258577B/en active IP Right Grant
- 2018-04-13 CL CL2018000953A patent/CL2018000953A1/es unknown
- 2018-04-13 ZA ZA2018/02451A patent/ZA201802451B/en unknown
- 2018-05-10 CO CONC2018/0004968A patent/CO2018004968A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018007395A2 (pt) | 2018-10-23 |
| KR102707502B1 (ko) | 2024-09-13 |
| TW201720796A (zh) | 2017-06-16 |
| MX2018004344A (es) | 2018-05-01 |
| JP6837482B2 (ja) | 2021-03-03 |
| UY36949A (es) | 2017-04-28 |
| IL258577B (en) | 2020-07-30 |
| EP3362442B1 (en) | 2020-01-29 |
| WO2017066402A1 (en) | 2017-04-20 |
| EA201890858A1 (ru) | 2018-09-28 |
| ES2774945T3 (es) | 2020-07-23 |
| CN108368087A (zh) | 2018-08-03 |
| EA034857B1 (ru) | 2020-03-30 |
| IL258577A (en) | 2018-05-31 |
| SG10201908839QA (en) | 2019-10-30 |
| US20180297954A1 (en) | 2018-10-18 |
| EP3362442A1 (en) | 2018-08-22 |
| KR20180067599A (ko) | 2018-06-20 |
| AU2016340264B2 (en) | 2021-01-07 |
| CN108368087B (zh) | 2022-04-12 |
| CA3001974A1 (en) | 2017-04-20 |
| PE20181197A1 (es) | 2018-07-23 |
| CL2018000953A1 (es) | 2018-08-24 |
| ZA201802451B (en) | 2020-01-29 |
| JP2018530591A (ja) | 2018-10-18 |
| MX376824B (es) | 2025-03-07 |
| AU2016340264A1 (en) | 2018-05-31 |
| US10392347B2 (en) | 2019-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018004968A2 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
| CO2018006662A2 (es) | Agonistas del receptor de apelina y métodos de uso | |
| CO2018007221A2 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) | |
| UY36705A (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| CO2018011105A2 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj) | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CL2017002122A1 (es) | Heterociclos bicíclicos como inhibidores de fgfr4 | |
| ECSP18060342A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos | |
| UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
| ECSP17031525A (es) | Composiciones novedosas, usos y métodos para hacerlas | |
| UY35908A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| MX2020006355A (es) | Pirrolidinamidas ii sustituidas. | |
| ECSP16074207A (es) | Pirazinas moduladoras de gpr6 |